Weight loss injections are becoming more widely discussed across the UK as NHS access expands and private prescribing remains available. In 2026, some eligible patients will be able to receive Wegovy through NHS specialist services, while others may access Wegovy injections through regulated private providers.
This article compares cost, delivery and clinical support for Wegovy in the UK. It outlines how NHS and private pathways differ in prescribing criteria, consultation processes and ongoing monitoring, so readers can understand what to check before choosing an option.
Prescribing Eligibility and Access Criteria
Access to Wegovy in the UK depends on whether treatment is sought through the NHS or a private provider. While both routes must follow UK licensing and prescribing standards, the eligibility thresholds and referral requirements differ.
NHS Eligibility Requirements
NHS access to Wegovy is governed by national guidance and local commissioning decisions. Eligibility is generally restricted to adults with a body mass index of 35 or above who also have at least one obesity-related condition, such as type 2 diabetes, hypertension or sleep apnoea. In some cases, individuals with a BMI between 30 and 35 may be considered if additional risk factors are present.
Referral through a GP and assessment by a specialist weight management service are usually required before Wegovy injections are approved. Evidence of previous structured lifestyle interventions may also form part of the assessment process.
Private Prescribing Criteria
Private access follows a different route. Regulated UK prescribers can assess patients through an online or in-clinic consultation. Clinical criteria still apply, as prescribers must follow MHRA licensing and professional standards.
Referral through NHS weight management services is not required. Eligibility decisions are made on an individual basis following medical screening, and treatment will only be supplied if considered clinically appropriate under the licensed indication.
Readers comparing pathways should consider whether they meet NHS thresholds and whether they are prepared for referral and potential waiting times, or whether a private assessment better suits their circumstances.
Cost Structure and Funding Arrangements
Cost is one of the clearest differences between NHS-funded and privately prescribed Wegovy injections. The way treatment is funded directly affects what patients pay and how charges are applied.
NHS Prescription Costs
Under the NHS pathway, patients who qualify for Wegovy pay the standard NHS prescription charge in England, unless they are exempt. The medication itself is funded by the NHS for those who meet the defined criteria.
Access may be phased regionally, which can influence when treatment becomes available. The total cost to the patient is therefore limited to standard prescription fees where applicable.
Private Pricing and Payment
Private prescriptions involve direct payment for the medication and associated clinical service. The cost typically includes the consultation, prescribing decision and supply of Wegovy. Prices vary between providers and may depend on dose strength and duration of treatment.
There is no NHS subsidy under this route. Patients reviewing private options should confirm what is included in the quoted price, including follow-up consultations and repeat prescribing fees.
Consultation and Approval Process
The pathway to receiving weight loss injections differs significantly between NHS and private settings. The steps required before treatment begins can influence waiting times and overall experience.
NHS Referral and Specialist Assessment
The NHS process begins with a GP appointment. If initial criteria appear to be met, referral to a specialist weight management service follows. Assessment may include a review of medical history, previous lifestyle interventions and current health status.
Treatment approval is made within the structure of an NHS obesity management programme. Wegovy injections are introduced as part of a broader care plan that includes behavioural and lifestyle support.
Private Clinical Assessment and Authorisation
Private providers operate under UK prescribing regulations but may conduct consultations remotely. Patients complete a medical questionnaire and may be asked for additional information to verify weight, BMI and medical history.
A qualified prescriber reviews the details before issuing a prescription. Some regulated pharmacies, such as The Independent Pharmacy, allow patients to purchase Wegovy online following a clinical assessment, provided it is appropriate under licensed indications and safety guidance.
When comparing these routes, readers should assess the level of documentation required, how quickly assessments are processed and how prescribing decisions are communicated.
Delivery and Supply of Wegovy
How Wegovy injections are supplied after approval depends on the prescribing pathway. Both NHS and private routes must follow safe dispensing standards, but delivery arrangements differ.
NHS Dispensing Arrangements
Through the NHS, Wegovy is supplied via standard NHS dispensing systems. Patients may collect prescriptions from a community pharmacy or receive them through a hospital or specialist clinic, depending on how local services are organised.
Supply is coordinated within the NHS framework and may be influenced by regional capacity or phased implementation plans.
Private Pharmacy Delivery
Private supply is typically arranged through a regulated pharmacy. After approval, Wegovy injections are dispensed and delivered to the patient’s address using secure, temperature-controlled packaging where required.
Delivery timelines vary by provider, but medication is issued only once a prescription has been authorised by a UK prescriber. Repeat supplies are subject to ongoing clinical review.
Patients comparing delivery options should consider convenience, turnaround time and how repeat prescriptions are managed under each pathway.
Monitoring, Follow-Up and Ongoing Support
Ongoing supervision forms part of both NHS and private prescribing, although the structure and frequency of follow-up may vary.
NHS Structured Support Programmes
NHS treatment with Wegovy forms part of a structured service. Patients are monitored within specialist weight management programmes and may receive support with diet, physical activity and behavioural strategies.
Regular reviews assess response to treatment, side effects and continued eligibility. Ongoing prescribing depends on meeting defined clinical milestones set out in national guidance.
Private Follow-Up and Review
Private providers also have a responsibility to monitor safety and suitability. Follow-up arrangements differ between providers. Some offer scheduled reviews, dose adjustment guidance and access to clinical support teams.
Others may require patients to request follow-up consultations at set intervals before repeat prescriptions are issued. All prescribing must comply with MHRA licensing and professional standards.
Individuals assessing support structures should review how frequently follow-up is provided, whether progress thresholds apply and how side effects are managed.
Reviewing Your Options for Weight Loss Injections in 2026
Weight loss injections in 2026 will be available in the UK through both NHS and private pathways, but the cost, delivery and support structures differ. NHS access is limited to patients who meet defined eligibility thresholds and involves referral through specialist services. Private access offers direct assessment through regulated prescribers, with full payment required.
Understanding these procedural differences allows individuals to review eligibility, funding arrangements, consultation methods and monitoring processes before making a decision about Wegovy.
